Calliditas Therapeutics AB (NAS:CALT)
$ 40.0001 -0.1599 (-0.4%) Market Cap: 1.08 Bil Enterprise Value: 1.10 Bil PE Ratio: 0 PB Ratio: 104.30 GF Score: 35/100

Q4 2021 Calliditas Therapeutics AB Earnings Call Transcript

Feb 24, 2022 / 01:30PM GMT
Release Date Price: $17.91 (+1.13%)
Renee Aguiar;Lucander;publ;CEO
Calliditas Therapeutics AB

()-

Welcome to this Q4 report. With me today, I have Andrew Udell, President, North America; Chris Ngai, VP, Market Access; Fredrik Johansson, Chief Financial Officer.

I'd like to draw your attention to the disclaimer page on Page 2. With regards to any forward-looking statements made, I refer you to the company's reports and other filings, including those which contain risk factors and other relevant information.

Please turn the page to Page #3. So this quarter, Calliditas has achieved a historic milestone in the company's history as we had our first commercial product approved in the U.S. under accelerated approval by the FDA. This is the result of our pioneering efforts in IgA nephropathy, which started over a decade ago, and we are delighted to be able to offer the first and only approved drug to this highly deserving patient population. The actual approval was provided on December 15, and this is under the branding of TARPEYO. And as I mentioned, it's the accelerated approval

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot